BDX vs LAB · P/E 34, rev $21.84B vs rev $174.4M
Becton Dickinson and Company (BDX) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. LAB currently screens at market cap $317.1M.
Not investment advice. Open the BDX and LAB stock pages for the full models.
Not investment advice.